Eurosurv. Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pi

[tetano]

• Alexis Sentís[SUP]1[/SUP] , Irina Kislaya[SUP]2[/SUP] , Nathalie Nicolay[SUP]3[/SUP] , Hinta Meijerink[SUP]4[/SUP] , Jostein Starrfelt[SUP]4[/SUP] , Iván Martínez-Baz[SUP]5,8[/SUP] , Jesús Castilla[SUP]5,8[/SUP] , Katrine Finderup Nielsen[SUP]6[/SUP] , Christian Holm Hansen[SUP]6[/SUP] , Hanne-Dorthe Emborg[SUP]6[/SUP] , Anthony Nardone[SUP]1[/SUP] , Tarik Derrough[SUP]3[/SUP] , Marta Valenciano[SUP]1[/SUP] , Baltazar Nunes[SUP]2[/SUP] , Susana Monge[SUP]7,9[/SUP] , the VEBIS-Lot4 working group[SUP]10[/SUP]

By employing a common protocol and data from electronic health registries in Denmark, Navarre (Spain), Norway and Portugal, we estimated vaccine effectiveness (VE) against hospitalisation due to COVID-19 in individuals aged ≥ 65 years old, without previous documented infection, between October 2021 and March 2022. VE was higher in 65–79-year-olds compared with ≥ 80-year-olds and in those who received a booster compared with those who were primary vaccinated. VE remained high (ca 80%) between ≥ 12 and < 24 weeks after the first booster administration, and after Omicron became dominant.

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.30.2200551#html_fulltext